Login to Your Account



Financings NEWS

Promentis Pharmaceuticals Inc., a Milwaukee-based company developing therapies for CNS, has completed a $26 million series C financing to help it advance its lead compound, SXC-2023, through phase II proof of concept.

LONDON – Pediatric medicines specialist Advicenne SA closed a €16 million round, providing the means to complete phase III development of ADV7103 for treating renal tubulopathy.

With multiple phase II studies of lead compound, mipsagargin, under its belt, Inspyr Therapeutics Inc. inked an agreement with private equity firm Milost Global Inc. for up to $100 million to fund the next stage of development.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: